Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMed

Stem Cell Therapy for the Treatment of Crohn's Disease; Current Obstacles and Future Hopes.

El-Nakeep S.

Randomized Controlled Trial on Autoimmune Research, published in Curr Stem Cell Res Ther (2022) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Curr Stem Cell Res Ther (2022)
Country
United Arab Emirates
Reported sample size
—
Source database
PubMed
PMID
34514993
DOI
10.2174/1574888X16666210910112403

Abstract (original English)

Crohn's disease (CD) is an autoimmune disease of the gastrointestinal tract, characterized by relapsing and remitting courses. The disease is debilitating in nature with three prominent phenotypic clinical presentations; fistulizing, stenosing, and inflammatory. Stem cells offer new hope for CD patients by modifying the immune response and progression of the healing process. This mini-review discusses the role of stem cells in treating CD, their effectiveness as a new therapy and their current limitations. The author conducted a literature review on recent randomized controlled trials and cohort studies concerned with the topic in question using the following keywords (Crohn's Disease, perianal fistula, Stem cell therapy, mesenchymal stem cells, remission). Clinical trials show that the stem cells are more effective in the CD-associated complex perianal fistula than the CD enteritis. At present, there are no standardized guidelines regarding dose of stem cells used, number of doses administered, route of administration, type of stem cells used. Only one group of researchers proposed a standardized procedure for injecting mesenchymal stem cells in complex perianal fistula, according to their own experience in clinical trials. Moreover, mesenchymal stem cells and their related types (placental, adipose tissue, umbilical tissue, etc.) are the safest and effective in clinical trial

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
Crohn DiseaseFemaleHumansMesenchymal Stem Cell TransplantationPlacentaPregnancyRectal FistulaTreatment Outcome

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research